Search Results - "Podrazil, Michal"

The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro by Stakheev, Dmitry, Taborska, Pavla, Strizova, Zuzana, Podrazil, Michal, Bartunkova, Jirina, Smrz, Daniel

“…Upregulated Wnt/β-catenin signaling is associated with increased cancer cell resistance and cancer cell-elicited immunosuppression. In non-neoplastic immune…”
Get full text

Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy by Podrazil, Michal, Taborska, Pavla, Stakheev, Dmitry, Rataj, Michal, Lastovicka, Jan, Vlachova, Alena, Pohunek, Petr, Bartunkova, Jirina, Smrz, Daniel

“…Coronavirus disease 2019 (COVID-19) vaccines effectively elicit humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2…”
Get full text

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines by Hensler, Michal, Rakova, Jana, Kasikova, Lenka, Lanickova, Tereza, Pasulka, Josef, Holicek, Peter, Hraska, Marek, Hrnciarova, Tereza, Kadlecova, Pavla, Schoenenberger, Andreu, Sochorova, Klara, Rozkova, Daniela, Sojka, Ludek, Drozenova, Jana, Laco, Jan, Horvath, Rudolf, Podrazil, Michal, Hongyan, Guo, Brtnicky, Tomas, Halaska, Michal J., Rob, Lukas, Ryska, Ales, Coosemans, An, Vergote, Ignace, Garg, Abhishek D., Cibula, David, Bartunkova, Jirina, Spisek, Radek, Fucikova, Jitka

“…Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical…”
Get full text

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer by Podrazil, Michal, Horvath, Rudolf, Becht, Etienne, Rozkova, Daniela, Bilkova, Pavla, Sochorova, Klara, Hromadkova, Hana, Kayserova, Jana, Vavrova, Katerina, Lastovicka, Jan, Vrabcova, Petra, Kubackova, Katerina, Gasova, Zdenka, Jarolim, Ladislav, Babjuk, Marek, Spisek, Radek, Bartunkova, Jirina, Fucikova, Jitka

“…We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with…”
Get full text

News in immunology by Bartůňková, Jiřina, Bloomfield, Markéta, Havlišová, Magdalena, Klocperk, Adam, Kubešová, Helena, Podrazil, Michal, Střížová, Zuzana, Šedivá, Anna

“…The field of immunology has undergone a very significant development in recent decades, which has been reflected especially in the beginning of this millennium…”
Get more information

Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer by Fucikova, Jitka, Podrazil, Michal, Jarolim, Ladislav, Bilkova, Pavla, Hensler, Michal, Becht, Etienne, Gasova, Zdenka, Klouckova, Jana, Kayserova, Jana, Horvath, Rudolf, Fialova, Anna, Vavrova, Katerina, Sochorova, Klara, Rozkova, Daniela, Spisek, Radek, Bartunkova, Jirina

“…Objective Immunotherapy of cancer has the potential to be effective mostly in patients with a low tumour burden. Rising PSA (prostate-specific antigen) levels…”
Get full text

Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients by Taborska, Pavla, Stakheev, Dmitry, Strizova, Zuzana, Vavrova, Katerina, Podrazil, Michal, Bartunkova, Jirina, Smrz, Daniel

“…Personalized peptide vaccination is a promising immunotherapeutic approach in prostate cancer (PCa). We therefore examined whether an approach, utilizing…”
Get full text

Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa by Spisek, Radek, Podrazil, Michal, Jarolim, Ladislav, Rozkova, Daniela, Fucikova, Jitka, Fialova, Anna, Bartunkova, Jirina

“…Abstract only…”
Get full text

Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca by Podrazil, Michal, Rozkova, Daniela, Fucikova, Jitka, Katina, Stanislav, Spisek, Radek, Bartunkova, Jirina

“…Abstract only…”
Get full text

Phase I/II clinical trials of dendritic cell-based immunotherapy in patients with the biochemical relapse of the prostate cancer by Spisek, Radek, Podrazil, Michal, Babjuk, Marek, Jarolim, Ladislav, Fucikova, Jitka, Fialova, Anna, Minarik, Ivo, Hromadkova, Hana, Bartunkova, Jirina

“…Abstract only e16002 Background: In order to have the highest impact on the control of tumor growth, cancer immunotherapy should be initiated as early in the…”
Get full text

Intensive physical activity increases peripheral blood dendritic cells by Suchánek, Ondřej, Podrazil, Michal, Fischerová, Barbara, Bočínská, Helena, Budínský, Vít, Stejskal, David, Špíšek, Radek, Bartůňková, Jiřina, Kolář, Pavel

“…We analyzed the frequency and absolute numbers of circulating myeloid and plasmacytoid DCs in peripheral blood and evaluated their maturation status to test…”
Get full text

FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer by Rožková, Daniela, Tišerová, Hana, Fučíková, Jitka, Lašt'ovička, Jan, Podrazil, Michal, Ulčová, Hana, Budínský, Vít, Prausová, Jana, Linke, Zdeněk, Minárik, Ivo, Šedivá, Anna, Špíšek, Radek, Bartůňková, Jiřina

“…Abstract Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the…”
Get full text